Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling

Barbara Oldrini(Spanish National Cancer Research Centre), Massimo Squatrito(AstraZeneca (United Kingdom))
Nature Communications
April 11, 2018
10.1038/s41467-018-03731-w
Cited by 73

Related Papers

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas
|Nature Communications|2020|195
Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4
|Nature|2022|88
NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness through the AP-1 transcription factor FOSL1
|bioRxiv (Cold Spring Harbor Laboratory)|2019|9
Somatic genome editing with the RCAS/TVA-CRISPR/Cas9 system for precision tumor modeling
|bioRxiv (Cold Spring Harbor Laboratory)|2017|6